Table 1.
SARS-CoV-2 susceptibility gene variant or haplotype | Risk estimated [OR] | Frequency [MAF] | References |
---|---|---|---|
TLR3, UNC93B1, TICAM1, TBK1, IRF3, IRF7, IFNAR1, IFNAR2 (autosomal-dominant model) | 9 | < 0.001 | Zhang et al. [20] |
IRF7, IFNAR1 (autosomal-recessive model) | > 50 | < 0.001 | Zhang et al. [20] |
rs769208985—missense variant of FURIN | N.A | < 0.001 | Latini et al. [71] |
rs150892504—missense variant of ERAP2 | N.A | 0.002 | Hu et al. [60] |
rs138763430—missense variant of BRF2 | N.A | 0.002 | Hu et al. [60] |
rs147149459—missense variant of ALOXE3 | N.A | 0.002 | Hu et al. [60] |
rs117665206—missense variant of TMEM181 | N.A | 0.006 | Hu et al. [60] |
rs114363287—missense variant of TMPRSS2 | N.A | 0.006 | Latini et al. [71] |
rs61756766—missense variant of TNFRSF13C | 12.3 | 0.008 | Russo et al. [61] |
rs7626962—missense variant of SCN5A | 8.7 | 0.008 | SeyedAlinaghi et al. [62] |
rs1805128—missense variant of KCNE1 | 9.0 | 0.009 | SeyedAlinaghi et al. [62] |
HLA-DRB*27:07 | N.A | 0.02 | Novelli et al. [51] |
rs72711165—intronic variant of TMEM65 | 1.2 | 0.02 | COVID-19 H.G.I. [66] |
rs115492982—intronic variant of MRPS21 | 2.5 | 0.02 | Dite et al. [63] |
rs74956615—3'UTR variant of TYK2 | 1.6 | 0.03 | Pairo-Castineira et al. [11] |
rs2034831—intronic variant of ITGA4 | 1.2 | 0.05 | Dite et al. [63] |
rs76374459—intronic variant of LZTFL1 | 1.2 | 0.05 | Dite et al. [63] |
rs35652899—intronic variant of LZTFL1 | 1.2 | 0.05 | Dite et al. [63] |
rs10490770—intronic variant of LZTFL1 | 2.0 | 0.06 | COVID-19 H.G.I. [66] |
rs333—CCR5-Δ32 | 0.7 | 0.07 | Cuesta-Llavona et al. [76] |
rs73064425—intronic variant of LZTFL1 | 2.1 | 0.08 | Pairo-Castineira et al. [11], Ellinghaus et al. [23] |
rs11385942—intronic variant of LZTFL1 | 1.8 | 0.07 | Ellinghaus et al. [23] |
rs1886814—intronic variant of FOXP4 | 1.3 | 0.07 | COVID-19 H.G.I. [66] |
rs76488148—intronic variant of GYG1 | 1.3 | 0.07 | Dite et al. [63] |
rs2271616—5'UTR variant of SLC6A20 | 1.1 | 0.08 | COVID-19 H.G.I. [66] |
HLA-DQB1*06:02 | N.A | 0.08 | Novelli et al. [51] |
rs143334143—intronic variant of CCHCR1 | 1.9 | 0.09 | Pairo-Castineira et al. [11] |
HLA-DRB1*15:01 | N.A | 0.10 | Novelli et al. [51] |
rs12252:G allele of IFITM3 | 2.2 | 0.13 | Alghamdi et al. [52] |
rs4801778—intronic variant of PLEKHA4 | 1.0 | 0.16 | COVID-19 H.G.I. [66] |
rs6598045—5'UTR variant of IFITM3 | N.A | 0.19 | Kim et al. [53] |
rs429358—missense variant of APOE | 2.3–2.4 | 0.20 | Kuo et al. [65] |
rs12610495—intronic variant of DPP9 | N.A | 0.25 | Moon et al. [41] |
rs12329760—intronic variant of TMPRSS2/MX1 | 0.9 | 0.25 | Andolfo et al. [72] |
rs2298661—missense variant of TMPRSS2/MX1 | 0.9 | 0.25 | Andolfo et al. [72] |
rs3787946—intronic variant of TMPRSS2/MX1 | 0.9 | 0.28 | Andolfo et al. [72] |
rs9983330—intronic variant of TMPRSS2/MX1 | 0.9 | 0.28 | Andolfo et al. [72] |
rs9380142—3'UTR variant of HLA-G | 13 | 0.29 | Pairo-Castineira et al. [11] |
rs2109069—intronic variant of DPP9 | 1.4 | 0.33 | Pairo-Castineira et al. [11], COVID-19 H.G.I. [66] |
rs9985159—intronic variant of TMPRSS2/MX1 | 0.9 | 0.33 | Andolfo et al. [72] |
Rs75603675—missense variant of TMPRSS2 | N.A | 0.36 | Latini et al. [71] |
rs1405655—intronic variant of NR1H2 | 1.1 | 0.37 | COVID-19 H.G.I. [66] |
rs12329760—missense variant of TMPRSS2 | 0.9 | 0.39 | Hou et al. [73] |
rs657152—intronic variant of ABO | 1.3 | 0.41 | Ellinghaus et al. [23] |
rs677800—intronic variant of ABO | N.A | 0.55 | Moon et al. [41] |
rs6020298—intronic variant of TMEM189-UBE2V1 | 1.2 | 0.58 | Wang et al. [74] |
rs10735079—intronic variant of OAS1/3 | 1.3 | 0.64 | Pairo-Castineira et al. [11] |
rs8065800—intronic variant of MAPT | 1.7 | 0.65 | COVID-19 H.G.I. [66] |
rs10774671—intronic, splicing variant of OAS1 | 1.1 | 0.67 | COVID-19 H.G.I. [66] |
rs13050728—intronic variant of IFNAR2 | 0.9 | 0.69 | COVID-19 H.G.I. [66] |
rs2236757—intronic variant of IFNAR2 | 1.3 | 0.71 | Pairo-Castineira et al. [11] |
rs3131294—intronic variant of NOTCH4 | 1.5 | 0.90 | Pairo-Castineira et al. [11] |
HLA-A*11 | N.A | N.A | Fricke-Galindo et al. [54] |
HLA-A*11:01:01:01 | 2.3 | N.A | Khor et al. [56] |
HLA-A*25:01 | N.A | N.A | Fricke-Galindo et al. [54] |
HLA-B*46:01 | 2.1 | N.A | Lin et al. [53], Fricke-Galindo et al. [54] |
HLA-B*51:01 | N.A | N.A | Fricke-Galindo et al. [54] |
HLA B*54:01 | 5.4 | N.A | Lin et al. [55] |
HLA-C*01 | N.A | N.A | Fricke-Galindo et al. [54] |
HLA-C*01:02 | N.A | N.A | Fricke-Galindo et al. [54] |
HLA-C*05 | N.A | N.A | Fricke-Galindo et al. [54] |
HLA-C*12:02:02:01-HLA*52:01:02:02 | 2.3 | N.A | Khor et al. [56] |
HLA-C*14:02 | N.A | N.A | Fricke-Galindo et al. [54] |
HLA-C*17 | N.A | N.A | Bonaccorsi et al. [57] |
HLA-DQB1*04 | N.A | N.A | Fricke-Galindo et al. [54] |
HLA-DQB1*08 | N.A | N.A | Fricke-Galindo et al. [54] |
HLA-E*0101/0103 | 2.1–2.7 | N.A | Vietzen et al. [58] |
KLRC2del | 2.6–7.1 | N.A | Vietzen et al. [58] |
ACE1 I/D genotype | 2.5 | N.A | Verma et al. [69] |
C9orf72 with HREs > 10 units | 2.4 | N.A | Zanella et al. [64] |
c.2129_2132del, p.Gln710Argfs*18—frameshift variant of TLR7 | N.A | N.A | van der Made et al. [42] |
c.2383G > T, p.Val795Phe—missense variant of TLR7 | N.A | N.A | van der Made et al. [42] |
c.644A > G, p.Asn215Ser—missense variant of TLR7 | N.A | N.A | Solanich et al. [43] |
c.2797 T > C, p.Trp933Arg—missense variant of TLR7 | N.A | N.A | Solanich et al. [43] |
c.901 T > C, p.Ser301Pro—missense variant of TLR7 | N.A | N.A | Fallerini et al. [44] |
c.3094G > A, p.Ala1032Thr— missense variant of TLR7 | N.A | N.A | Fallerini et al. [44] |
c.2759G > A, p.Arg920Lys—missense variant of TLR7 | N.A | N.A | Fallerini et al. [44] |
c.863C > T, p.Ala288Val—missense variant of TLR7 | N.A | N.A | Fallerini et al. [44] |
c.1342C > T, p.Ala448Val—missense variant of TLR7 | N.A | N.A | Fallerini et al. [44] |
c.655G > A, p.Val219Ile—missense variant of TLR7 | N.A | N.A | Fallerini et al. [44] |
rs140312271—missense variant of ACE2 | N.A | N.A | Novelli et al. [75] |
MAF Major Allele Frequency; N.A. Not Applicable; OR Odds Ratio